The Role of Phosphodiesterase Inhibitors in Incretin Secretion

Trial Profile

The Role of Phosphodiesterase Inhibitors in Incretin Secretion

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Feb 2017

At a glance

  • Drugs Roflumilast (Primary) ; Sitagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 20 Sep 2016 Status changed from recruiting to completed.
    • 21 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top